Señales en vivo de RLAY | Maximiza tus Ganancias con Getagraph.com

VENDER 116758 min ago

@ $9.40

Emitido: 14 feb 2024 @ 13:07

Retorno: -25.11%

Señal anterior: feb 14 - 11:58

Señal anterior: Comprar

Retorno: 1.68 %

Live Chart Being Loaded With Signals

Commentary (3 may 2024 @ 16:00):

Stats
Volumen de hoy	1.17M
Volumen promedio	1.24M
Capitalización de mercado	923.50M
EPS	$0 ( 2024-05-02 )
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-2.52
ATR14	$0.0110 (0.16%)

Insider Trading

Date	Person	Action	Amount	type
2024-04-29	Rahmer Peter	Sell	1 345	Common Stock
2024-04-29	Adams Brian	Sell	1 623	Common Stock
2024-04-29	Catinazzo Thomas	Sell	1 695	Common Stock
2024-04-29	Bergstrom Donald A	Sell	2 686	Common Stock
2024-03-27	Catinazzo Thomas	Sell	348	Common Stock

INSIDER POWER
88.11
Last 99 transactions
Buy: 4 152 455 \| Sell: 364 261

Volumen Correlación

Largo: -0.05 (neutral)

Corto: -0.45 (neutral)

Signal:(44.995) Neutral

Relay Therapeutics, Inc. Correlación

10 Correlaciones Más Positivas
TXG	0.941
NEOG	0.926
GLPG	0.926
AMPH	0.925
MAXN	0.923
DCFC	0.92
BGFV	0.917
BIRD	0.914
NVTS	0.913
PRTS	0.911

10 Correlaciones Más Negativas
GRCL	-0.916
MSAC	-0.902
IVCB	-0.899
FTGC	-0.899
GGAL	-0.898
TZPS	-0.897
TRMR	-0.891
GHRS	-0.889
RETA	-0.889
AEYE	-0.887

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Relay Therapeutics, Inc. Correlación - Moneda/Commodity

0.34
( neutral )

0.21
( neutral )

0.00
( neutral )

0.79
( moderate )

-0.76
( moderate negative )

Relay Therapeutics, Inc. Finanzas

Annual	2023
Ingresos:	$25.55M
Beneficio Bruto:	$20.28M (79.37 %)
EPS:	$-2.79

FY	2023
Ingresos:	$25.55M
Beneficio Bruto:	$20.28M (79.37 %)
EPS:	$-2.79

FY	2022
Ingresos:	$1.38M
Beneficio Bruto:	$-2.75M (-199.06 %)
EPS:	$-2.27

FY	2021
Ingresos:	$3.03M
Beneficio Bruto:	$3.03M (100.00 %)
EPS:	$-3.93

Financial Reports:

No articles found.

Relay Therapeutics, Inc.

Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The company's lead product candidates include RLY-4008, an oral small molecule inhibitor of fibroblast growth factor receptor 2 (FGFR2), which is in a first-in-human clinical trial for patients with advanced or metastatic FGFR2-altered solid tumors; RLY-2608, a lead mutant-PI3Ka inhibitor program that targets phosphoinostide 3 kinase alpha; and RLY-1971, an oral small molecule inhibitor of protein tyrosine phosphatase Src homology region 2 domain-containing phosphatase-2 that is in Phase 1 trial in patients with advanced solid tumors. It has collaboration and license agreements with D. E. Shaw Research, LLC to research certain biological targets through the use of D. E. Shaw Research computational modeling capabilities focused on analysis of protein motion to develop and commercialize compounds and products directed to such targets; and Genentech, Inc. for the development and commercialization of RLY-1971. The company was formerly known as Allostery, Inc. and changed its name to Relay Therapeutics, Inc. in December 2015. Relay Therapeutics, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.